These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 21123824)
1. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Janikashvili N; LaCasse CJ; Larmonier C; Trad M; Herrell A; Bustamante S; Bonnotte B; Har-Noy M; Larmonier N; Katsanis E Blood; 2011 Feb; 117(5):1555-64. PubMed ID: 21123824 [TBL] [Abstract][Full Text] [Related]
2. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884 [TBL] [Abstract][Full Text] [Related]
3. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Wang Y; Sparwasser T; Figlin R; Kim HL Cancer Res; 2014 Apr; 74(8):2217-28. PubMed ID: 24574514 [TBL] [Abstract][Full Text] [Related]
4. [Effect of apoptosis of CD4+ CD25+ regulatory T lymphocytes on polarization of helper T lymphocytes and potential interventional influence of Xuebijing injection in septic rats]. Dai XG; Yao YM; Ai YH Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Mar; 21(3):135-8. PubMed ID: 19278580 [TBL] [Abstract][Full Text] [Related]
11. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4 Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845 [TBL] [Abstract][Full Text] [Related]
12. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. Larmonier N; Cantrell J; Lacasse C; Li G; Janikashvili N; Situ E; Sepassi M; Andreansky S; Katsanis E J Leukoc Biol; 2008 Apr; 83(4):1049-59. PubMed ID: 18174364 [TBL] [Abstract][Full Text] [Related]
13. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. Hiura T; Kagamu H; Miura S; Ishida A; Tanaka H; Tanaka J; Gejyo F; Yoshizawa H J Immunol; 2005 Oct; 175(8):5058-66. PubMed ID: 16210609 [TBL] [Abstract][Full Text] [Related]
14. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells. Kawahara M; Takaku H Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871 [TBL] [Abstract][Full Text] [Related]
15. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Li G; Zeng Y; Chen X; Larmonier N; Sepassi M; Graner MW; Andreansky S; Brewer MA; Katsanis E Clin Exp Immunol; 2007 Apr; 148(1):136-45. PubMed ID: 17349014 [TBL] [Abstract][Full Text] [Related]
16. Identification of a human Th1-like IFNγ-secreting Treg subtype deriving from effector T cells. Venigalla RK; Guttikonda PJ; Eckstein V; Ho AD; Sertel S; Lorenz HM; Tretter T J Autoimmun; 2012 Dec; 39(4):377-87. PubMed ID: 22824211 [TBL] [Abstract][Full Text] [Related]
17. Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function. Pillemer BB; Xu H; Oriss TB; Qi Z; Ray A Eur J Immunol; 2007 Aug; 37(8):2082-9. PubMed ID: 17621372 [TBL] [Abstract][Full Text] [Related]
18. Derp1-modified dendritic cells attenuate allergic inflammation by regulating the development of T helper type1(Th1)/Th2 cells and regulatory T cells in a murine model of allergic rhinitis. Yu S; Han B; Liu S; Wang H; Zhuang W; Huang Y; Zhang R Mol Immunol; 2017 Oct; 90():172-181. PubMed ID: 28802126 [TBL] [Abstract][Full Text] [Related]
19. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253 [TBL] [Abstract][Full Text] [Related]
20. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]